Altimmune (ALT) director Vipin Garg logs RSU vesting and tax share surrender

Rhea-AI Filing Summary

Altimmune, Inc. director Vipin K. Garg reported RSU vesting and related share movements. On January 27, 2026, 41,200 Restricted Stock Units converted into the same number of Altimmune common shares at a stated price of $0 per share.

To cover taxes on the RSU vesting, 17,898 common shares were surrendered to the issuer at a price of $6.18 per share. After these transactions, Garg directly held 402,450 Altimmune common shares and 123,600 RSUs, which vest in substantially equal annual installments over four years following January 27, 2025.

Insider Trade Summary

41,200 shares exercised/converted

Mixed 3 txns

Insider Garg Vipin K

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	41,200	$0.00	--
Exercise	Common Stock, par value $0.0001	41,200	$0.00	--
Tax Withholding	Common Stock, par value $0.0001	17,898	$6.18	$111K

Holdings After Transaction: Restricted Stock Units — 123,600 shares (Direct); Common Stock, par value $0.0001 — 420,348 shares (Direct)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garg Vipin K

(Last) (First) (Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	01/27/2026		M		41,200	A	$0(1)	420,348	D
Common Stock, par value $0.0001	01/27/2026		F(2)		17,898	D	$6.18	402,450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/27/2026		M			41,200	(3)	(3)	Common Stock, par value $0.0001	41,200	$0	123,600	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

2. Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

3. The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

	/s/ Gregory Weaver, as Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Altimmune (ALT) director Vipin K. Garg report?

Altimmune (ALT) director Vipin K. Garg reported the vesting of 41,200 Restricted Stock Units into common shares on January 27, 2026. The filing also shows related share withholding to cover taxes and updated common share and RSU holdings afterward.

How many Altimmune (ALT) RSUs vested and converted to stock in this Form 4?

The Form 4 shows that 41,200 Altimmune (ALT) Restricted Stock Units vested and converted into 41,200 common shares at a stated price of $0 per share. Each RSU represents a contingent right to receive one share of common stock when vested.

Why were 17,898 Altimmune (ALT) shares surrendered in this insider filing?

The filing states that 17,898 Altimmune (ALT) common shares were surrendered to the issuer solely to cover taxes associated with the vesting of RSUs. This is reported under transaction code F at a price of $6.18 per share.

How many Altimmune (ALT) shares does Vipin K. Garg hold after the reported transactions?

After the reported transactions, Vipin K. Garg directly holds 402,450 Altimmune (ALT) common shares. The Form 4 also reports that he beneficially owns 123,600 Restricted Stock Units following the RSU vesting and tax withholding share surrender.

What is the vesting schedule for Vipin K. Garg’s Altimmune (ALT) RSUs?

The RSUs reported in the Altimmune (ALT) filing vest in substantially equal annual installments over four years following January 27, 2025. Vesting is subject to the reporting person’s continued service through each applicable vesting date and the RSUs have no expiration date.

What do the transaction codes M and F mean in this Altimmune (ALT) Form 4?

In this Altimmune (ALT) Form 4, code M reflects the conversion of 41,200 RSUs into common shares at a stated price of $0. Code F reflects a vesting-related tax transaction where 17,898 shares were surrendered to the issuer to cover withholding taxes.